Purpose of the development: For the correction of prooxidant-antioxidant homeostasis in conditions of acute hypoxic hypoxia, and affects the phenomenon of adaptation to the acute action of cold. For the treatment of cardiovascular, neurological diseases, for the combination therapy of cancer and tuberculosis diseases. To increase the endurance of athletes to stress.

Recommended application field: Medicine.

Technical characteristic: The toxicity of the drug is low (LD50 100,000 mg / kg). Dosage form - tablets of 0.1 g.

Advantages over analogues: It does not cause dyspeptic phenomena, is not contraindicated in hypoglycemic conditions and does not potentiate the effect of barbiturates. Yaсton is a low-toxic compound that does not adversely affect the function of parenchymal organs.

The development stage readiness: Tested experimental exploitation order

Description of the development:
()
Yaсton affects the content of substrates of energy metabolism and the activity of dehydrogenases in the myocardium with dosed cold action. An important property of Yaсton is the ability to reduce the toxicity of many chemical compounds, as well as the side effects of anti-tuberculosis and anti-tumor drugs.

Information about newness of the development:
there are Ukrainian patents -- 1 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua